By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Schering Corp. et al.v. Kappos
1:11-cv-00457; filed March 1, 2011 in the District Court of the District of Columbia
• Plaintiffs: Schering Corp.; Merck & Co., Inc.
• Defendant: David Kappos
Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent No. 7,304,078 ("Thrombin Receptor Antagonists," issued December 4, 2007). View the complaint here.
Cellectis S.A. v. Precision Biosciences Inc.
1:11-cv-00173; filed March 1, 2011 in the District Court of Delaware
Infringement of U.S. Patent No. 7,897,372 ("I-CreI Meganuclease Variants With Modified Specificity, Method of Preparation and Uses Thereof," issued March 1, 2011) based on Precision's use of its Directed Nuclease Editor technology. View the complaint here.
Precision BioSciences, Inc. v. Cellectis S.A.
5:11-cv-00091; filed March 1, 2011 in the Eastern District of North Carolina
Declaratory judgment of non-infringement and invalidity of U.S. Patent No. 7,897,372 ("I-CreI Meganuclease Variants With Modified Specificity, Method of Preparation and Uses Thereof," issued March 1, 2011) based on Precision's use of its Directed Nuclease Editor technology. View the complaint here.
Cephalon Inc. et al.v. Mylan Pharmaceuticals Inc. et al.
1:11-cv-00164; filed February 24, 2011 in the District Court of Delaware
• Plaintiffs: Cephalon Inc.; CIMA Labs Inc.
• Defendants: Mylan Pharmaceuticals Inc.; Mylan Inc.
Infringement of U.S. Patent Nos. 6,200,604 ("Sublingual Buccal Effervescent," issued March 13, 2001) and 6,974,590 (same title, issued December 13, 2005) following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Cephalon's Fentora® (fentanyl citrate buccal tablets, used to treat breakthrough pain in adult patients with cancer). View the complaint here.
Takeda Pharmaceutical Co., LTD et al.v. Handa Pharmaceuticals, LLC
5:11-cv-00840; filed February 23, 2011 in the Northern District of California
• Plaintiffs: Takeda Pharmaceutical Co., LTD; Takeda Pharmaceuticals North America, Inc; Takeda Pharmaceuticals LLC; Takeda Pharmaceuticals America, Inc.
• Defendant: Handa Pharmaceuticals, LLC
Infringement of U.S. Patent Nos. 6,462,058 ("Benzimidazole Compound Crystal," issued October 8, 2002), 6,664,276 (same title, issued December 16, 2003), 6,939,971 (same title, issued September 6, 2005), 7,285,668 ("Process for the Crystallization of (R)- or (S)-Lansoprazole," issued October 23, 2007), and 7,790,755 ("Controlled Release Preparation," issued September 7, 2010) following a Paragraph IV certification as part of Handa's filing of an ANDA to manufacture a generic version of Takeda's Dexilant® (dexlansoprazole, used for the treatment of all grades of erosive esophagitis, maintaining healing of esophagitis, and treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease). View the complaint here.
Comments